key: cord-1052944-zemxp1hd authors: Lladó, I.; Butrón, B.; Sampedro‐Ruiz, R.; Fraga, J.; de Argila, D. title: Pityriasis rubra pilaris after Vaxzevria® COVID‐19 vaccine date: 2021-08-12 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17542 sha: bca5de58f6bfb91f04847c96c78832ce87fa5a6b doc_id: 1052944 cord_uid: zemxp1hd A 63-year-old Caucasian woman presented with rapidly developing lesions on both hands, elbows and feet, 9 days after she received the first dose of the Oxford-AstraZeneca COVID-19 vaccine ChAdOx1-S n-CoV19 (Vaxzevria®). To the editor, A 63-year-old Caucasian woman presented with rapidly developing lesions on both hands, elbows and feet, 9 days after she received the first dose of the Oxford-AstraZeneca COVID-19 vaccine ChAdOx1-S n-CoV19 (Vaxzevriaâ, AstraZeneca, Cambridge, UK). On physical examination, she presented orange-red waxy palmoplantar keratoderma, symmetrical and sharply demarcated orange-red squamous plaques on the elbows, follicular keratotic orange-red papules on the dorsal aspect of hands and feet, and subtle erythema and fine diffuse scaling on the scalp, with associated pruritus. Onycholysis with orange border could also be seen on both great toenails (Fig. 1) . She only had a history of familial hypercholesterolemia, along with moderate hepatic steatosis and a past statin-induced myopathy, but was otherwise healthy. She was only on cholestyramine resin, which she had been taking for many years. There was no previous history of infections, significant UV exposition, traumatisms or other associated diseases. HIV serology was negative. The only potential trigger was the first dose of the Vaxzevriaâ vaccine, which was administered 9 days before disease onset. She had suffered from COVID-19 in March 2020, with anosmia as the main symptom. Two biopsies, taken from the elbow and the dorsal aspect of one foot, showed a psoriasiform dermatitis with hypergranulosis, hyperkeratosis and alternating orto-and parakeratosis in a 'checkerboard pattern', as well as a sparse lymphohistiocytic perivascular infiltrate in the papillary dermis. All these features were consistent with clinical suspicion of pityriasis rubra pilaris (PRP). Within a few days, the patient experienced worsening of the lesions, with newly appearing orange keratotic papules and plaques on both forearms, lower back and lower limbs. Then, Acitretin therapy was started at an initial dose of 20 mg per day. Currently, vaccination against SARS-CoV-2 is being carried out worldwide. Vaxzevriaâ vaccine is one of the currently approved vaccines in the European Union for this purpose, and consists of a replication-deficient chimpanzee adenoviral vector ChAdOx1, containing the SARS-CoV-2 structural surface glycoprotein antigen (spike protein) gene. 1 A wide variety of cutaneous adverse effects after COVID-19 vaccination are currently being described. [2] [3] [4] [5] [6] The majority of them develop at the injection site, and can be classified into early-onset reactions (i.e. pain, pruritus, swelling, erythema), with a median time-to-onset of 1 day, and delayed large local reactions, with a median time-to-onset of 7 days after the first dose or 2 days after the second dose, and a median duration of 3-4 days. 2 However, a fair amount of cutaneous adverse effects develops at a location distant from the injection site. These reactions can also be classified into immediate reactions (i.e. pruritus, urticaria, flushing, angioedema and anaphylaxis), with a time-to-onset lower than 4 h, and delayed reactions, which include urticarial rash, morbilliform rash, pityriasis rosea-like rash, herpes simplex or varicella zoster reactivation, filler inflammatory reactions, erythromelalgia and pernio, among others. 2 Most of the publications on this issue are referred exclusively to mRNA vaccines. [2] [3] [4] Data addressing cutaneous adverse effects secondary to non-mRNA based COVID-19 vaccines are still lacking. Post-vaccine PRP has been rarely reported in the literature. To our knowledge, only four cases have been published to date, concerning two infant males (17 and 19 months old) and two women (32 and 47 years old). The vaccines involved were diphtheria-tetanus-polio, influenza (Tetagripâ, Sanofi Pasteur, Lyon, France) and measles-mumps-rubella, with a time-to-onset of the lesions ranging from 10 to 18 days 7-10 ( Table 1) . Although the association between COVID-19 vaccination and PRP could be entirely casual, we cannot rule out a causal relationship since the lesions were temporally associated with vaccination and showed acute onset and rapid development. Accordingly, this could be the first reported case of PRP induced by COVID-19 vaccination. Safety and efficacy of the ChA-dOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registrybased study of 414 cases Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers COVID-19 Vaccines and the Skin: the landscape of cutaneous vaccine reactions worldwide Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study Pityriasis rubra pilaris after vaccination Pityriasis rubra pilaris occurring after vaccination with diphtheria-pertussis-tetanus and oral poliovirus vaccines A case of pityriasis rubra pilaris induced by DTPolio Vaccination Pityriasis rubra pilaris triggered by Tetragripâ vaccine The patients in this manuscript have given written informed consent for publication of their case details.